News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Calistoga Pharmaceuticals Appoints Andrew Guggenhime as Chief Financial Officer


9/28/2010 10:30:29 AM

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the appointment of Andrew L. Guggenhime as Chief Financial Officer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES